Patents by Inventor Youichi Nakano
Youichi Nakano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240083867Abstract: A compound of the formula (I) or a salt thereof (R represents methyl group or fluorine atom) having an mPGES-1 inhibitory activity and useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of such diseases as inflammation, pain, or rheumatism.Type: ApplicationFiled: February 1, 2022Publication date: March 14, 2024Applicant: ASKA PHARMACEUTICAL CO., LTD.Inventors: Makoto OKADA, Youichi NAKANO, Takashi NOSE, Satoshi MAEDA, Tomoaki WATANABE
-
Publication number: 20240041899Abstract: Provided is a solid preparation having an excellent stability and being useful for treating or improving (or alleviating) a urination disorder regardless of the degree or presence of prostatomegaly. The solid preparation contains a 2-oxapregnane compound represented by the following formula (1) as an active ingredient, and a carrier. In the formula, R1 to R3 each represent an alkyl group such as a methyl group, R4 represents an alkylcarbonyl group such as an acetyl group, X represents a halogen atom such as a chlorine atom, and Y represents a hydroxyl group or oxo group bonded to the 11-position, 15-position, or 16-position of the steroid skeleton. The carrier contains a first carrier and/or a second carrier; the first carrier is not a metal salt-form, and the second carrier is a polyvalent metal salt-form of an inorganic acid.Type: ApplicationFiled: December 17, 2021Publication date: February 8, 2024Applicant: ASKA Pharmaceutical Co., Ltd.Inventors: Sakiko KITAMURA, Kazuhiro SASAKI, Hiroshige KATAOKA, Asuka OZAWA, Hideo KOBAYASHI, Atsushi SHINBO, Youichi NAKANO, Yuta ITO, Junichi WATANABE
-
Publication number: 20220331340Abstract: Provided is a urination disorder-improving agent useful for treating or improving (or alleviating) a urination disorder regardless of the degree or presence of prostatomegaly. The urination disorder-improving agent contains a 2-oxapregnane compound represented by the following formula (1) as an active ingredient. (In the formula, R1 to R3 represent an alkyl group such as methyl group, R4 represents an alkylcarbonyl group such as acetyl group, X represents a halogen atom such as a chlorine atom, Y represents a hydroxyl group or oxo group bonded to the 11-position, 15-position, or 16-position of the steroid skeleton.Type: ApplicationFiled: January 29, 2020Publication date: October 20, 2022Applicant: ASKA Pharmaceutical Co., Ltd.Inventors: Hideo KOBAYASHI, Atsushi SHINBO, Youichi NAKANO, Yuta ITO, Junichi WATANABE
-
Publication number: 20220037707Abstract: A battery pack includes battery groups, a holder, a positive electrode-connection bus bar, and a negative electrode-connection bus bar. The positive electrode-connection bus bar is connected to the positive electrode terminal having a highest potential in the first battery group and the second battery group which are electrically connected to each other in series. The negative electrode-connection bus bar is connected to the negative electrode terminal having a lowest potential in the first battery group and the second battery group which are electrically connected to each other in series. The positive electrode-connection bus bar and the negative electrode-connection bus bar are connected to the holder.Type: ApplicationFiled: October 19, 2021Publication date: February 3, 2022Inventors: Takayuki NAKAJIMA, Youichi Nakano, Hisayuki Suematsu, Yukinori Takahashi
-
Patent number: 10710967Abstract: A compound represented by the formula (1), or a salt thereof (X represents carbonyl group, or sulfonyl group; R1 represents hydrogen atom, a halogen atom, an alkyl group, an alkanoyl group, cyano group, or carboxyl group; R2 represents an alkyl group, a cyclic carbon group, or a heterocyclic group; R3 represents hydrogen atom, or 1 to 3 substituents; R4 and R5 represents hydrogen atom, a halogen atom, or an alkyl group; and R6 represents an alkyl group, or an alkoxy group), which has an mPGES-1 inhibitory action, and is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of inflammation, pain, rheumatism, and the like.Type: GrantFiled: October 28, 2016Date of Patent: July 14, 2020Assignee: ASKA PHARMACEUTICAL CO., LTD.Inventors: Makoto Okada, Youichi Nakano, Takashi Nose, Takahiro Nishimoto, Satoshi Maeda
-
Publication number: 20200071280Abstract: A compound represented by the formula (1), or a salt thereof (X represents carbonyl group, or sulfonyl group; R1 represents hydrogen atom, a halogen atom, an alkyl group, an alkanoyl group, cyano group, or carboxyl group; R2 represents an alkyl group, a cyclic carbon group, or a heterocyclic group; R3 represents hydrogen atom, or 1 to 3 substituents; R4 and R5 represents hydrogen atom, a halogen atom, or an alkyl group; and R6 represents an alkyl group, or an alkoxy group), which has an mPGES-1 inhibitory action, and is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of inflammation, pain, rheumatism, and the like.Type: ApplicationFiled: October 28, 2016Publication date: March 5, 2020Applicant: ASKA PHARMACEUTICAL CO., LTD.Inventors: Makoto OKADA, Youichi NAKANO, Takashi NOSE, Takahiro NISHIMOTO, Satoshi MAEDA
-
Publication number: 20190280353Abstract: A cell pack includes a battery group which includes a plurality of secondary battery cells each having a pair of wide-width surfaces, a pair of narrow-width surfaces, a bottom surface, and an external terminal formed to face the bottom surface; a housing which has one side surface, another side surface adjacent to the one side surface, and a facing side surface facing the other side surface and houses the battery group; and a pack external terminal which is disposed adjacent to the facing side surface of the housing and is connected to the external terminal of the battery group, wherein the secondary battery cells of the battery group are stacked so that the wide-width surfaces face each other, the battery group is housed in the housing in a state in which a wide-width surface of a secondary battery cell of a lowermost layer and the one side surface of the housing are coupled to each other so as to be capable of conducting heat therebetween and the bottom surfaces of the secondary battery cells and the otherType: ApplicationFiled: February 5, 2018Publication date: September 12, 2019Inventors: Yukinori TAKAHASHI, Youichi NAKANO, Takayuki NAKAJIMA, Hisayuki SUEMATSU
-
Publication number: 20190260096Abstract: A battery pack includes: battery groups which are formed by stacking a plurality of battery cells each including a terminal surface having one side in a longitudinal direction including a positive electrode terminal and the other side in the longitudinal direction including a negative electrode terminal, and a pair of stacked surfaces adjacent to the terminal surface so that the terminal surfaces of the plurality of battery cells are directed in the same direction and the positive electrode terminal and the negative electrode terminal are alternately arranged, the stacked surfaces facing each other; and a holder which accommodates two or more kinds of electric components electrically connected to the battery groups and is disposed so that the electric components face a surface in which the positive electrode terminals and the negative electrode terminals of the battery groups are arranged.Type: ApplicationFiled: February 5, 2018Publication date: August 22, 2019Inventors: Takayuki NAKAJIMA, Youichi NAKANO, Hisayuki SUEMATSU, Yukinori TAKAHASHI
-
Patent number: 9040536Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: GrantFiled: July 31, 2014Date of Patent: May 26, 2015Assignee: ASKA PHARMACEUTICAL CO., LTD.Inventors: Makoto Okada, Shuichiro Sato, Kenji Kawade, Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi
-
Publication number: 20140336197Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: ApplicationFiled: July 31, 2014Publication date: November 13, 2014Inventors: Makoto OKADA, Shuichiro SATO, Kenji KAWADE, Kotaro GOTANDA, Atsushi SHINBO, Youichi NAKANO, Hideo KOBAYASHI
-
Patent number: 8829000Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: GrantFiled: September 14, 2012Date of Patent: September 9, 2014Assignee: ASKA Pharmaceutical Co., Ltd.Inventors: Makoto Okada, Shuichiro Sato, Kenji Kawade, Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi
-
Publication number: 20130225572Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: ApplicationFiled: September 14, 2012Publication date: August 29, 2013Inventors: Makoto OKADA, Shuichiro SATO, Kenji KAWADE, Kotaro GOTANDA, Atsushi SHINBO, Youichi NAKANO, Hideo KOBAYASHI
-
Patent number: 8377944Abstract: This invention provides thienopyrimidine derivatives of the formula, wherein R1 stands for hydrogen atom, an alkyl group or the like; R2 stands for a hydrogen atom, an alkyl or amino group or the like, R3 stands for an alkyl, alkenyl or alkylthio group or the like or a group Y—X—; or R2 and R3 may together form tetramethylene group; X standing for a direct bond or linking group such as CH2, CH(OH), S, O, NH; Y standing for a substituted or unsubstituted aromatic carbocyclic, aromatic heterocylic, cycloalkyl or saturated heterocyclic group or the like; Z stands for S or O, and n is 0 or an integer of 1 to 4, or salts thereof, which exhibit an inhibitory effect on PDE9, and are therefore useful for prevention or treatment of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria associated with prostatic hyperplasia, urolithiasis, Alzheimer's disease, chronic obstructive pulmonary disease, myocardial infarction, thrombosis, diabetes and the like.Type: GrantFiled: August 14, 2012Date of Patent: February 19, 2013Assignee: ASKA Pharmaceutical Co., Ltd.Inventors: Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi, Makoto Okada, Akira Asagarasu
-
Publication number: 20130023546Abstract: This invention provides thienopyrimidine derivatives of the formula, wherein R1 stands for hydrogen atom, an alkyl group or the like; R2 stands for a hydrogen atom, an alkyl or amino group or the like, R3 stands for an alkyl, alkenyl or alkylthio group or the like or a group Y—X—; or R2 and R3 may together form tetramethylene group; X standing for a direct bond or linking group such as CH2, CH(OH), S, O, NH; Y standing for a substituted or unsubstituted aromatic carbocycylic, aromatic heterocylic, cycloalkyl or saturated heterocyclic group or the like; Z stands for S or O, and n is 0 or an integer of 1 to 4, or salts thereof, which exhibit an inhibitory effect on PDE9, and are therefore useful for prevention or treatment of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria associated with prostatic hyperplasia, urolithiasis, Alzheimer's disease, chronic obstructive pulmonary disease, myocardial infarction, thrombosis, diabetes and the like.Type: ApplicationFiled: August 14, 2012Publication date: January 24, 2013Inventors: Kotaro GOTANDA, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi, Makoto Okada, Akira Asagarasu
-
Patent number: 8299080Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: GrantFiled: December 12, 2007Date of Patent: October 30, 2012Assignee: Aska Pharmaceutical Co., Ltd.Inventors: Makoto Okada, Shuichiro Sato, Kenji Kawade, Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi
-
Patent number: 8293754Abstract: This invention provides thienopyrimidine derivatives of the formula, wherein R1 stands for hydrogen atom, an alkyl group or the like; R2 stands for a hydrogen atom, an alkyl or amino group or the like, R3 stands for an alkyl, alkenyl or alkylthio group or the like or a group Y—X—; or R2 and R3 may together form tetramethylene group; X standing for a direct bond or linking group such as CH2, CH(OH), S, O, NH; Y standing for a substituted or unsubstituted aromatic carbocycylic, aromatic heterocylic, cycloalkyl or saturated heterocyclic group or the like; Z stands for S or O, and n is 0 or an integer of 1 to 4, or salts thereof, which exhibit an inhibitory effect on PDE9, and are therefore useful for prevention or treatment of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria associated with prostatic hyperplasia, urolithiasis, Alzheimer's disease, chronic obstructive pulmonary disease, myocardial infarction, thrombosis, diabetes and the like.Type: GrantFiled: June 13, 2006Date of Patent: October 23, 2012Assignee: Aska Pharmaceutical Co., Ltd.Inventors: Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi, Makoto Okada, Akira Asagarasu
-
Publication number: 20100113484Abstract: Disclosed is a treating agent of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria in benign prostatic hyperplasia or urolithiasis, which comprises a compound having PDE9-inhibiting activity as the active ingredient.Type: ApplicationFiled: December 12, 2007Publication date: May 6, 2010Applicant: ASKA PHARMACEUTICAL CO., LTD.Inventors: Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi, Makoto Okada, Akira Asagarasu
-
Publication number: 20100048556Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: ApplicationFiled: December 12, 2007Publication date: February 25, 2010Inventors: Makoto Okada, Shuichiro Sato, Kenji Kawade, Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi
-
Publication number: 20090203703Abstract: This invention provides thienopyrimidine derivatives of the formula, wherein R1 stands for hydrogen atom, an alkyl group or the like; R2 stands for a hydrogen atom, an alkyl or amino group or the like, R3 stands for an alkyl, alkenyl or alkylthio group or the like or a group Y—X—; or R2 and R3 may together form tetramethylene group; X standing for a direct bond or linking group such as CH2, CH(OH), S, O, NH; Y standing for a substituted or unsubstituted aromatic carbocycylic, aromatic heterocylic, cycloalkyl or saturated heterocyclic group or the like; Z stands for S or O, and n is 0 or an integer of 1 to 4, or salts thereof, which exhibit an inhibitory effect on PDE9, and are therefore useful for prevention or treatment of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria associated with prostatic hyperplasia, urolithiasis, Alzheimer's disease, chronic obstructive pulmonary disease, myocardial infarction, thrombosis, diabetes and the like.Type: ApplicationFiled: June 13, 2006Publication date: August 13, 2009Inventors: Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi, Makoto Okada, Akira Asagarasu
-
Patent number: D861593Type: GrantFiled: September 29, 2017Date of Patent: October 1, 2019Assignee: Hitachi Automotive Systems, Ltd.Inventors: Takayuki Nakajima, Hisayuki Suematsu, Youichi Nakano